[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591693":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":39,"centralContacts":43,"locations":51,"responsibleParty":123,"collaborators":125,"id":128,"slug":129,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":130,"sex":136,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":25,"studyType":142,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":54,"whyStopped":25,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Erasca, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ERAS-0015 Monotherapy Dose Optimization.","EXPERIMENTAL","Escalating doses of ERAS-0015 administered orally.",[13],"Drug: ERAS-0015",{"label":15,"type":10,"description":16,"interventionNames":17},"ERAS-0015 Combination Dose Optimization","ERAS-0015 administered orally with another investigational agent.",[18],"Drug: ERAS-0015 in combination",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ERAS-0015","ERAS-0015 Administered orally",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"ERAS-0015 in combination","ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.",[15],[31,32,33,34,35,36,37,38],"pembrolizumab","KEYTRUDA ®","panitumumab","Vectibix","gemcitabine","Gemzar","nab-paclitaxel","Abraxane",[40],{"name":41,"affiliation":5,"role":42},"Gerri Lee","STUDY_DIRECTOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":25,"email":48},"Erasca Clinical Team Team","CONTACT","+1-858-465-6511","clinicaltrials@erasca.com",{"name":50,"role":46,"phone":25,"phoneExt":25,"email":25},"Les Brail, Study Director, PhD",[52,66,75,85,94,104,113],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":25},"Florida Cancer Specalists","RECRUITING","Sarasota","Florida","34232","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-82.53065,27.33643,{"lat":64,"lon":63},{"facility":67,"status":54,"city":68,"state":56,"zip":69,"country":58,"countryCode":59,"cosmosGeoPoint":70,"geoPoint":74,"contacts":25},"Moffitt Cancer Center","Tampa","33612",{"type":61,"coordinates":71},[72,73],-82.45843,27.94752,{"lat":73,"lon":72},{"facility":76,"status":54,"city":77,"state":78,"zip":79,"country":58,"countryCode":59,"cosmosGeoPoint":80,"geoPoint":84,"contacts":25},"Massachusetts General Hospital (MG)","Boston","Massachusetts","02114",{"type":61,"coordinates":81},[82,83],-71.05977,42.35843,{"lat":83,"lon":82},{"facility":86,"status":54,"city":87,"state":87,"zip":88,"country":58,"countryCode":59,"cosmosGeoPoint":89,"geoPoint":93,"contacts":25},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":61,"coordinates":90},[91,92],-74.00597,40.71427,{"lat":92,"lon":91},{"facility":95,"status":54,"city":96,"state":97,"zip":98,"country":58,"countryCode":59,"cosmosGeoPoint":99,"geoPoint":103,"contacts":25},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":61,"coordinates":100},[101,102],-95.36327,29.76328,{"lat":102,"lon":101},{"facility":105,"status":54,"city":106,"state":97,"zip":107,"country":58,"countryCode":59,"cosmosGeoPoint":108,"geoPoint":112,"contacts":25},"University of Texas at Tyler","Tyler","75701",{"type":61,"coordinates":109},[110,111],-95.30106,32.35126,{"lat":111,"lon":110},{"facility":114,"status":54,"city":115,"state":116,"zip":117,"country":58,"countryCode":59,"cosmosGeoPoint":118,"geoPoint":122,"contacts":25},"NEXT Virginia","Fairfax","Virginia","22031",{"type":61,"coordinates":119},[120,121],-77.30637,38.84622,{"lat":121,"lon":120},{"type":124,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[126],{"name":127,"class":6},"Merck Sharp & Dohme LLC","100591693","phase-1-a-study-of-eras-0015-in-patients-with-advanced-or-metastatic-solid-tumors-100591693",false,"NCT06983743","A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors","A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors","AURORAS-1","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing and able to give written informed consent\n* Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts.\n* There is no available standard systemic therapy available for the patient's tumor histology and\u002For molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort.\n* Able to swallow oral medication\n* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Adequate cardiovascular, hematological, liver, and renal function\n* Willing to comply with all protocol-required visits, assessments, and procedures\n\nExclusion Criteria:\n\n* Previous treatment with a RAS inhibitor\n* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015\n* Received prior palliative radiation within 14 days of Cycle 1, Day 1\n* Have primary central nervous system (CNS) tumors\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial","ALL","18 Years","99 Years",{"count":140,"type":141},600,"ESTIMATED","INTERVENTIONAL",[144],"PHASE1","The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.",[147],"Metastatic Solid Tumors",[149,150,151,152,153,31,32,33,34,154,155,156,157,158,159],"Solid Tumor","Advanced Solid Tumor","solid malignancies","Targeted therapy","Molecular alterations","Metastatic Solid Tumor","Neoplasms","Colorectal Cancer","Non-small cell lung cancer (NSCLC)","Newly diagnosed Pancreatic Ductal Adenocarcinoma","NSCLC patients previously treated with a KRAS G12c inhibitor","2026-06-23",{"date":162,"type":163},"2026-06-26","ACTUAL",{"date":165,"type":163},"2025-06-05",{"date":167,"type":141},"2028-12-01",{"name":5,"class":6},7]